Softwr

Healthcare · head to head

Fujifilm Synapse vs Woebot Health

Fujifilm Synapse logo

Fujifilm Synapse

Healthcare

Enterprise imaging platform covering PACS, VNA, cardiology and 3D from Fujifilm Healthcare

From
On request
Rated
-
Full reviewWebsite
Woebot Health logo

Woebot Health

Healthcare

Conversational CBT chatbot that withdrew from consumer distribution and now sells only to payers and providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Fujifilm Synapse pACS, VNA, Cardiovascular and 3D are separately licensed and separately versioned, so an enterprise deployment means four upgrade cycles and four support relationships under one brand rather than one platform upgrade.; Woebot Health the company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • They diverge on capability: Fujifilm Synapse covers Synapse PACS, Woebot Health covers Scripted CBT dialogue.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Fujifilm Synapse and Woebot Health actually diverge.

Attributes where Fujifilm Synapse and Woebot Health differ
AttributeFujifilm SynapseWoebot Health
PlatformsWeb, Windows, iOS, AndroidiOS, Android, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Fujifilm Synapse

  • Synapse PACS
  • Synapse VNA
  • Synapse Cardiovascular
  • Synapse 3D
  • Synapse Mobility
  • Deconstructed PACS support
  • Cloud services

Only in Woebot Health

  • Scripted CBT dialogue
  • Mood tracking
  • Crisis routing
  • Between-session support
  • Payer deployment
  • Provider copilot positioning
  • Research licensing
  • Population reporting

What people use each for

The jobs each tool is most often brought in to do.

Fujifilm Synapse

  • A hospital replacing PACS that wants the archive decoupled from its scanner vendor so future modality purchases stay competitivenot Woebot Health
  • A health system consolidating radiology, cardiology, ophthalmology and wound images into one vendor neutral archive with a single retention policynot Woebot Health
  • An outpatient imaging chain that needs one worklist across multiple sites and radiologists reading remotelynot Woebot Health
  • A site pursuing a deconstructed PACS strategy that wants to replace the viewer later without touching the archivenot Woebot Health

Woebot Health

  • A health plan wanting a low intensity behavioural health option for members on a waiting list for therapynot Fujifilm Synapse
  • A provider organisation offering structured between-session CBT practice to patients already in treatmentnot Fujifilm Synapse
  • A research group running a trial that needs a clinically scripted rather than generative conversational agent for safety reasonsnot Fujifilm Synapse
  • A payer targeting a specific population such as postpartum members where scripted CBT content already existsnot Fujifilm Synapse

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Fujifilm Synapse

  • PACS, VNA, Cardiovascular and 3D are separately licensed and separately versioned, so an enterprise deployment means four upgrade cycles and four support relationships under one brand rather than one platform upgrade.
  • Synapse 3D is licensed by concurrent user and sized from average concurrency, which leaves radiologists queued for advanced visualisation at the morning reading peak and forces an unplanned licence purchase.
  • As an independent informatics vendor Fujifilm has less privileged access to proprietary modality data than Philips or Siemens have on their own scanners, so some vendor specific post processing is not available.
  • The vendor neutral archive absorbs non DICOM object types only after per specialty configuration work, and departments such as ophthalmology and dermatology usually need bespoke ingestion projects that were not in the original scope.
  • Migrating a decade of priors from a legacy archive is a large professional services line that Fujifilm quotes separately, and these migrations regularly run past the contracted go live date.

Woebot Health

  • The company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • It is not an FDA cleared treatment for any indication, so it cannot be positioned to members as therapy and cannot substitute for a covered behavioural health benefit.
  • The scripted, non-generative design that makes it safe also makes it feel rigid next to current conversational AI, and engagement drops off quickly once users hit the edges of the script.
  • Published evidence is short-horizon symptom change in selected populations, mostly young adults, with little evidence of durable benefit or effect at whole-population scale.
  • With consumer distribution gone, the remaining business depends on a small number of payer and provider contracts, so a buyer should assume real vendor continuity risk over a multi-year term.

Pricing, plan by plan

Fujifilm Synapse

On request
  • Synapse$undefined/year
    • Each module licensed separately: PACS, VNA, Cardiovascular, 3D
    • Priced by annual study volume and concurrent diagnostic users
    • Synapse 3D licensed by concurrent user, separate from PACS

Woebot Health

On request
  • Woebot for payers and providers$undefined/year
    • Contracted per member per month or as a population licence
    • Sold to health plans and provider organisations, not to employers or individuals
    • No consumer purchase route since the app closed in June 2025

Which should you pick?

Choose Fujifilm Synapse if

  • You need synapse pacs.
  • You work on Web, Windows, iOS, Android.
  • You also want synapse vna.
Fujifilm Synapse review

Choose Woebot Health if

  • You need scripted cbt dialogue.
  • You work on iOS, Android, Web.
  • You also want mood tracking.
Woebot Health review

Questions people ask

Is Fujifilm Synapse or Woebot Health better?
Neither clearly leads. Fujifilm Synapse starts at On request and Woebot Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Fujifilm Synapse or Woebot Health?
Fujifilm Synapse starts at On request and Woebot Health at On request.
Does Fujifilm Synapse or Woebot Health run on more platforms?
Fujifilm Synapse runs on Web, Windows, iOS, Android. Woebot Health runs on iOS, Android, Web.
What is Fujifilm Synapse best used for?
Fujifilm Synapse is most often used for a hospital replacing pacs that wants the archive decoupled from its scanner vendor so future modality purchases stay competitive, a health system consolidating radiology, cardiology, ophthalmology and wound images into one vendor neutral archive with a single retention policy, an outpatient imaging chain that needs one worklist across multiple sites and radiologists reading remotely, a site pursuing a deconstructed pacs strategy that wants to replace the viewer later without touching the archive. Of those, a hospital replacing pacs that wants the archive decoupled from its scanner vendor so future modality purchases stay competitive and a health system consolidating radiology, cardiology, ophthalmology and wound images into one vendor neutral archive with a single retention policy are not what Woebot Health is typically brought in for.
What can Fujifilm Synapse do that Woebot Health cannot?
Fujifilm Synapse covers Synapse PACS, Synapse VNA, Synapse Cardiovascular, Synapse 3D. Woebot Health covers Scripted CBT dialogue, Mood tracking, Crisis routing, Between-session support.

Answered from the vendors’ own pages

Fujifilm Synapse: Is Synapse one product or several?

Several. Synapse PACS, Synapse VNA, Synapse Cardiovascular and Synapse 3D are separately licensed products under one brand. Price and scope each one individually.

Woebot Health: Is Woebot still available?

Not to consumers. The consumer app closed in June 2025. The company continues to offer the product to payers, providers and researchers.

Fujifilm Synapse: Do I have to buy Fujifilm scanners?

No. Fujifilm sells Synapse independently of imaging hardware, which is a large part of why it wins competitive PACS replacements at mixed fleet sites.

Woebot Health: Is it FDA cleared?

No. It held Breakthrough Device designation but never obtained marketing authorisation, and the founder cited the cost of that pathway as the reason for closing the consumer app.

Fujifilm Synapse: Does Synapse publish pricing?

No. Pricing is quoted by study volume, concurrent users, module mix and storage capacity.

Woebot Health: Is it generative AI?

Historically no. The dialogue is clinician-written and rule-based, a deliberate safety choice that limits how naturally it converses.

Fujifilm Synapse: Can Synapse VNA store non radiology images?

Yes, including visible light, ophthalmology and wound photography, but each specialty typically needs its own ingestion and metadata configuration project.

Woebot Health: What does the evidence show?

Randomised studies reported reduced depressive symptoms over short periods in selected populations, notably young adults. That is symptom change in a trial, not demonstrated population outcomes.

Share

Related pages

More on Fujifilm Synapse

More on Woebot Health

Keep looking

Other head to heads